Skip to main content

Table 6 The combined synergizing effects of Obatoclax on cellular apoptosis

From: BH3-mimetics: recent developments in cancer therapy

Cancer Cell Type Combined Apoptosis Ref
AML U937, HL-60, MV4–11 sorafenib [195]
Bladder HT1197 paclitaxel [196]
Bladder T24, TCCSuP, 5637 cisplatin [197]
Cholangiocarcinoma KMCH, KMBC, TFK, TRAIL [198]
Colon HCT116, HCT-8, fluorouracil [199]
Esophageal CaES-17 MG132 [200]
Glioblastoma Patient samples SAHA, LBH589 [201]
Small cell lung H82, H526, DMS79, H196, H1963, H69 bortezomib and carfilzomib synergized [202]
Non-small cell Lung LoVo, RKO, HCT116 oxaliplatin resistance [203]
Neuroblastoma SK-N-DZ, IGR-NB8 hydroxychloroquine/cisplatin/
Pancreas BxPC-3 gemcitabine [205]
Pancreas PANC-1 and BxPC-3 TRAIL [206]
Pancreas BxPC-3, HPAC chloroquine [207]
Pancreas BxPC-3, HPAC, MIAPaCa-2, PANC-1, AsPC-1, CFPAC-1 AZD2281 synergized [208]
Thyroid KTC-1, BCPAP LY3009120/vemurafenib resistance [209]
  1. The cancer types are highlighted in bold (left column), non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the column on the right (Ref). Abbreviations: AML Acute Myelogenous Leukemia